Karo Bio will focus on infectious disease, steroids and bone regeneration drugs. The research, conducted by a staff that is expected to reach more than 100 scientists by late 1989, will be carried out at the Huddings Hospital near here. In addition to having exclusive European licensing rights to products it develops, the new company will gain European rights to the nasal drug delivery system evolved by California Biotech that is undergoing clinical trials for use with substances such as insulin and human growth hormone.

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?